Immune-Mediated Inflammatory Diseases
Research activity includes severe, treatment-refractory immune-mediated inflammatory diseases with a focus on rheumatoid arthritis, systemic sclerosis, primary Sjögren’s disease, and idiopathic inflammatory myopathy.
- BCMAxCD3 bispecific T-cell engaging therapy
- Severe refractory autoimmune inflammation
- Connective tissue disease
- Inflammatory myopathy
The therapeutic emphasis is on complex autoimmune conditions with persistent disease activity despite prior treatment.
Vasculitis and Autoantibody-Driven Disease
Clinical research also covers active, treatment-refractory ANCA-associated vasculitis with ANCA-IgG positivity, reflecting interest in autoantibody-mediated vascular inflammation.
- CD3/CD20 bispecific T-cell engager therapy
- ANCA-positive vasculitis
- B-cell and T-cell targeting
- Seroconversion outcomes
This area centers on refractory vasculitic disease and immune pathways linked to pathogenic antibody production.
Chronic Urticaria and Complement Pathways
Another focus is chronic spontaneous urticaria, particularly in adults with persistent symptoms despite H1-antihistamine treatment and with stratification by IgE profile.
- Complement Factor D inhibition
- Urticaria activity
- IgE-related subgroups
- Antihistamine-resistant disease
The therapeutic interest lies in immune modulation of mast-cell driven skin disease and complement-related mechanisms.
Attention-Deficit Hyperactivity Disorder and Depression
Research extends to adults with ADHD and moderate to severe depression, addressing overlapping neuropsychiatric symptoms in the adult population.
- Adult ADHD
- Depressive symptoms
- Psychiatric comorbidity
- Central nervous system treatment
This area reflects interest in conditions where attention regulation and mood disorders coexist.
